Ovid therapeutics Inc
Closed
SectorHealthcare
2.48 -8.82
Overview
Share price change
24h
Min
2.57
Max
2.81
Income | -27M -17M |
|---|---|
EPS | -0.125 |
Profit margin | -2,366.017 |
Employees | 23 |
EBITDA | -4.7M -17M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +105.13% upside |
Next Earnings | 12 Aug 2026 |
|---|
Market Cap | 4.4M 487M |
|---|---|
Previous open | 11.3 |
Previous close | 2.48 |
Ovid therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ovid therapeutics Inc Forecast
Price Target
By TipRanks
105.13% upside
12 Months Forecast
Average 5.6 USD 105.13%
High 7 USD
Low 4 USD
Based on 7 Wall Street analysts offering 12 month price targets forOvid therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ovid therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.